|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2000-1-19
|
|
pubmed:abstractText |
Very high purity factor VIII (FVIII) concentrates (plasma-derived or produced by recombinant-DNA technology) were used to achieve immune tolerance in five patients with high-responding inhibitors to FVIII. The mean time required for inhibitor disappearance was 5 months. Four out of five patients showed normalisation of the half-life of infused FVIII after 8-18 months of treatment with 100 IU FVIII/kg body weight administered once daily. Highly purified FVIII products thus appear to be suitable for achieving immune tolerance without negative effects on endogenous von Willebrand factor levels and activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0042-9007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
77 Suppl 1
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
65-9
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10529692-Adolescent,
pubmed-meshheading:10529692-Antibodies, Monoclonal,
pubmed-meshheading:10529692-Antigens,
pubmed-meshheading:10529692-Child, Preschool,
pubmed-meshheading:10529692-Cloning, Molecular,
pubmed-meshheading:10529692-Factor VIII,
pubmed-meshheading:10529692-Hemophilia A,
pubmed-meshheading:10529692-Humans,
pubmed-meshheading:10529692-Immune Tolerance,
pubmed-meshheading:10529692-Recombinant Proteins,
pubmed-meshheading:10529692-Time Factors,
pubmed-meshheading:10529692-von Willebrand Factor
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.
|
|
pubmed:affiliation |
Ospedale Nuovo Pellegrini, Divisione de Ematologiaosi, Centro Emofilia e Trombosi, Napoli, Italia.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
